Key Highlights

● Lakefront repurchased 106,060 ordinary shares between September 21 and September 25, 2026, at an average of EUR 26.36 per share.

● The total cost was EUR 2,795,740.67, with prices paid ranging from EUR 24.68 to EUR 28.34 per share.

● Purchases fall under the repurchase program announced on June 9, 2026 and run through an independent financial intermediary.

● After the week's activity, the company says it holds 1,633,594 of its own ordinary shares as of September 25.

Lakefront Biotherapeutics NV (NASDAQ:LKFT), a Belgian biotechnology company listed on both Euronext and Nasdaq under the symbol LKFT, furnished a Form 6-K to the U.S. Securities and Exchange Commission on September 29, 2026. The filing attaches a press release reporting its weekly share repurchase activity. Between September 21 and September 25, 2026, the company bought back 106,060 of its own ordinary shares for a total of EUR 2,795,740.67, an average of EUR 26.36 per share.

The Week's Repurchases

The press release describes the purchases as taking place "within the framework of the repurchase program announced on June 9, 2026." It says the shares were bought through a discretionary mandate given to an independent financial intermediary, meaning the company has delegated day-to-day execution of the trades to a third party rather than placing each order itself.

The release includes a table with the daily volume, average price and total cost for each of the five trading days. It also reports a price range for the week, with a lowest price paid of EUR 24.68 and a highest of EUR 28.34 per share. The transaction detail is broken out by trading venue, and the venues listed in the release are XAMS, TQEX, AQEU and CEUX, which are market identifier codes for European trading venues.

After the week's activity, the company states that "as of market close on September 25, 2026, Lakefront holds 1,633,594 of its own ordinary shares."

About the Company

In the boilerplate section of the release, Lakefront describes itself as "a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need." Its portfolio is centered on immunology and inflammation. The release names gamgertamig, which it characterizes as "a potential first-in-class and best-in-class BCMAxCD3 T-cell engager for autoimmune diseases."

What the Form 6-K Is

Lakefront files as a foreign private issuer, so it uses Form 6-K to furnish to the SEC information it has made public in its home market or elsewhere. The cover document for this filing is short. It gives the company's address as Schaliënhoevedreef 20T, 2800 Mechelen, Belgium, and its SEC file number as 001-37384, and it is signed by Ying Deng as Authorized Officer, dated September 29, 2026.

The 6-K states that the press release is incorporated by reference into the company's registration statements on Form S-8, which relate to stock option and employee benefit plans. The filing lists thirteen file numbers, ranging from 333-204567 to 333-292050. Incorporation by reference means the press release becomes part of those registration statements. The filing does not announce a new securities offering.

Lakefront Holds 1,633,594 Own Shares After Buyback Week

The release covers the September 21 to 25 window, during which the company bought 106,060 shares at an average of EUR 26.36 under the program announced on June 9, 2026.

After the week's activity, Lakefront holds 1,633,594 of its own ordinary shares, with purchases executed through a discretionary mandate given to an independent financial intermediary.